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Genetically modified macrophages 
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to the inflamed brain in transgenic 
Parkin Q311X(A) mice: importance 
of administration routes
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Cell‑based drug delivery systems have generated an increasing interest in recent years. We 
previously demonstrated that systemically administered macrophages deliver therapeutics to 
CNS, including glial cell line‑derived neurotrophic factor (GDNF), and produce potent effects in 
Parkinson’s disease (PD) mouse models. Herein, we report fundamental changes in biodistribution 
and brain bioavailability of macrophage‑based formulations upon different routes of administration: 
intravenous, intraperitoneal, or intrathecal injections. The brain accumulation of adoptively 
transferred macrophages was evaluated by various imaging methods in transgenic Parkin Q311(X)A 
mice and compared with those in healthy wild type littermates. Neuroinflammation manifested in PD 
mice warranted targeting macrophages to the brain for each route of administration. The maximum 
amount of cell‑carriers in the brain, up to 8.1% ID/g, was recorded followed a single intrathecal 
injection. GDNF‑transfected macrophages administered through intrathecal route provided significant 
increases of GDNF levels in different brain sub‑regions, including midbrain, cerebellum, frontal cortex, 
and pons. No significant offsite toxicity of the cell‑based formulations in mouse brain and peripheral 
organs was observed. Overall, intrathecal injection appeared to be the optimal administration route 
for genetically modified macrophages, which accomplished targeted gene delivery, and significant 
expression of reporter and therapeutic genes in the brain.
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder in people over 65 years old, 
and one of the leading sources of disability affecting one million people in the  US1. Furthermore, it is projected 
to reach 1.24 million in 2030. PD is characterized by the lack of the neurotransmitter, dopamine, due to a loss 
of dopaminergic neurons within the Substantia Nigra parts compacta (SNpc). Regrettably, there are no effective 
treatments or cures known. Currently available treatments provide only short-term benefits that is followed 
by the increased neurodegeneration and resistance to the existing therapies. Moreover, offsite toxicity leads 
to multiple complications, including dyskinesia, anxiety, depression, fatigue and  pain2. In particular, the most 
common treatment of PD with L-DOPA that aims to increase the levels of dopamine in striatum may result in 
some improvements in motor functions at the beginning followed by fast decreases in dopaminergic activity and 
progression of the  disease3. Clearly, the new treatment paradigms for nervous system disorders, and specifically, 
for PD to stop and reverse neurodegeneration must be developed.
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PD is associated with brain  inflammation4, microglia activation, and oxidative stress, all of which affect neu-
ronal, astrocyte, and microglia survival by activating apoptotic  processes5–8, and leading to neuronal  demise9. 
Several lines of evidence suggest that mitochondrial dysfunction and oxidative stress have a central role in the 
dopaminergic neurodegeneration of  PD10. In fact, the majority of CNS disorders have in common an inflamma-
tory  component11. In this respect, specialized cells of the immune system, including monocytes, macrophages, 
stem cells, and T cells, exhibit an intrinsic homing property of migrating toward the sites of injury, inflammation 
and tumor via the processes known as diapedesis and  chemotaxis12. Thus, immunocytes are reported to cause 
blood–brain barrier (BBB) breakdown following brain  inflammation13–16 trafficking primarily between adjacent 
endothelial cells, i.e. paracellulary through the junctional  complexes17,18. Even in the healthy brain, perivascular 
macrophages, which reside on the parenchymal side of endothelial cells, originate from circulating phagocytes, 
monocytes and macrophages. It is well documented that under pathological conditions, the rate of transport of 
immunocytes to the inflamed brain tissues is further  elevated14–16,19–22. In particular, these cells have shown a 
remarkable capability to cross an intact BBB with 80% turnover in 3 months23,24. Such frequent migration offers 
a unique opportunity to design novel cell-based drug formulations.
Two approaches are developed in the field of cell-mediated therapeutics. First approach utilizes the host 
cells that are loaded with a drug, usually incorporated into a protective container, and then carry the drug to 
the disease  side25–29. Importantly, immunocytes have a high rate of endocytosis that allows efficient accumula-
tion of micro- and nanoparticles with incorporated drugs within intracytoplasmic endosomes. These drugs are 
subsequently released from the cell-carriers through the recycling processes that include exocytosis. However, 
one of the main obstacles of this approach is efficient disintegration of the entrapped foreign particles by mono-
cytes. Furthermore, loading of cytotoxic anticancer compounds requires the exceptionally strong protection of 
cell-carriers against their toxic cargo.
Second approach is based on the genetic modification of living cells to overexpress therapeutic  molecules30–32. 
In particular, neural stem cells (NSC) were transfected to express vascular endothelial growth factor (VGEF), or 
glial cell-line neurotrophic factor (GDNF), or neurturin (NTN), and examined for the brain delivery of these 
therapeutics to treat  PD33–35. Furthermore, bone marrow-derived macrophages (BMM) and microglia were also 
used in PD mouse  models36,37. Specifically, BMM were transduced ex vivo with lentivirus to express GDNF, and 
adaptively transferred to recipient mice. GDNF-BMM decreased neuroinflammation and neurodegeneration 
that leaded to regeneration of axons in SNpc and improved motor functions in PD  mice36. Likewise, genetically 
modified NSC were investigated for the delivery of neurotrophic  factors38–42 to treat Alzheimer’s disease. Clearly, 
drug delivery systems based on living cells could serve as a new therapeutic approach.
Overall, drug delivery systems based on living cells can act as “Trojan horses” carrying concealed drug cargoes 
across impermeable barriers, such as the BBB or blood-tumor barrier, to the disease sites. These features make 
immunocytes attractive candidates for the CNS drug delivery. The neuroinflammation developed in the course 
of disease serves as a cue for recruitment of immune cells from periphery to the brain, providing the necessary 
spatial, temporal, and dosage control at targeted tissues.
Based on this exciting and promising therapeutic concept, we developed a novel platform technology for 
brain delivery of therapeutic agents, in which monocytes/macrophages are loaded ex vivo with therapeutics, 
and adoptively transferred to a disease-affected animal. Following adoptive transfer, drug-loaded macrophages 
accumulate at the disease tissues in the brain and exert therapeutic effect. We demonstrated the potential of this 
approach for the treatment of PD using diverse therapeutics (proteins and recombinant DNA) delivered within 
macrophages in toxin-induced PD mouse  models43–48, and transgenic Parkin Q311X(A)  mice49. In these prior 
studies, autologous bone marrow-derived macrophages (BMM) were administered into the blood stream by 
intravenous (i.v.) injections. The present study evaluates whether the route of systemic administration can alter 
the biodistribution and brain bioavailability of the cell-carriers in transgenic Parkin Q311X(A) mouse model. 
To assess brain and peripheral organ distribution of BMM in living mice, we used different imaging techniques, 
including In vivo Imaging System (IVIS), Positron Emission Tomography (PET), and Magnetic Resonance 
Imaging (MRI). We convincingly demonstrated significant brain accumulation of BMM injected through dif-
ferent administration routes in Parkin Q311X(A) mice. Importantly, the intrathecal (i.t.) route resulted in the 
superior BMM brain accumulation when compared to intravenous (i.v.) or intraperitoneal (i.p.) administrations. 
We hypothesized that the mild brain inflammation manifested in the transgenic PD mouse model warranted 
targeted gene delivery to the brain. We further evaluated the delivery of reporter and therapeutic genes to the 
brain in Parkin Q311X(A) mice by genetically-modified BMM. For the first time, we report significant increases 
in the expression of GDNF brain levels after a single i.t. injection of GDNF-transfected macrophages, providing 
additional evidence for clinical relevance of this cell-based delivery system for PD treatment.
Results
Biodistribution of autologous macrophages in Parkin Q311(X)A mice by bioluminescence 
imaging. We evaluated i.v., i.p., and i.t. administration routes of BMM in Parkin Q311(X)A mice by IVIS 
(Fig. 1). To visualize the cell-carriers, their lipid membranes were labeled with a hydrophobic dye, DIR  (DiIC18(7); 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide). In this experiment, we used maximal dose 
and volume of cell suspension allowed for each route of administration (specifically, 4 × 106 cells/200 µL/mouse 
for i.v. and i.p. injections, and 1 × 106 cells/50 µL/mouse for i.t. injections). These experimental conditions were 
chosen to replicate following therapeutic efficacy investigations. Significant levels of DIR-BMM were recorded 
in PD mouse brain at 24–72 h time frame for all three routes of administration (Figs. 1A–C). Lower fluorescence 
signals during the first hours in dorsal images were likely due to the fact that most DIR-BMM circulated in the 
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We also administered same doses of DIR-BMM in the age-matched wild type (WT) healthy mice (Fig. 2). DIR-
BMM fluorescence was recorded in the brain of WT mice at 24–72 h after i.v. and i.p. injections (Fig. 2A–C). Very 
little if any brain fluorescence was recorded in the brain in healthy animals after i.t. administration of DIR-BMM. 
Additional supine images of WT littermates injected with DIR-BMM are also shown on Supplementary Figure S2.
The live imaging data in PD and WT mice was quantified by IVIS Aura software (Fig. 3). For all routes of 
administration, the signals of DIR-BMM in the brain in living PD mice (Fig. 3A, filled symbols) were significantly 
greater than those in healthy WT littermates (Fig. 3A, empty symbols) throughout the entire observation period. 
Individual values of the DIR-BMM fluorescence for each animal are presented in Supplementary Tables S1 and 
S2. Remarkably, signals of DIR-BMM in the PD mouse brain at later time points (48–72 h) were significantly 
greater (p < 0.05) after i.p. and i.t. injections (Fig. 3A, filled squares and triangles, respectively), when compared 
to the signal observed after the i.v. injections (Fig. 3A, filled circles). Keeping in mind that the i.t. injected dose 
of DIR-BMM was four times less than those injected via i.p. and i.v. routes, the i.t. administration appears to be 
preferred for macrophage-based CNS delivery.
The mice were sacrificed at the endpoint (72 h), perfused to eliminate the blood, and the main organs were 
imaged by IVIS for PD (Fig. 1D–F) and WT groups (Fig. 2D–F). The quantification of fluorescence levels at 
necropsy suggested that the fluorescence signal of DIR-BMM decreased in the row: liver > lungs ≅ spleen > kid-
ney > brain (Fig. 3B). For all routes of administration the greatest DIR-BMM signal was detected in the liver, 
although, considerable signal was also seen in the brain (Figs. 1B, 3A), where DIR-BMM could possibly transport 
via the lymphatic  system50. Significantly greater accumulation of DIR-BMM in the PD mouse brain were detected 
compared with their WT littermates, especially in case of i.t. and i.p. injections (Fig. 3B, insert). These results 
suggest that systemically administered macrophages migrate to the sites of inflammation and accumulate in 
the brain of transgenic Parkin Q311(X)A mice that is in good agreement with our earlier observations made in 
PD mice with acute toxin-induced brain  inflammation43–48. One should keep in mind that quantification IVIS 
images of isolated organs reflects total fluorescence of whole organ, therefore high fluorescence count in liver 
may be not only due to the greater accumulation of DIR-BMM in this organ, but also to the overall larger liver 
Figure 1.  Biodistribution of DIR-labeled BMM in Parkin Q311(X)A mice by IVIS. DIR-labeled BMM were 
administered in PD mice (12 mo. of age) (A, D) i.v. (4 × 106 cells/200 µL), (B, E) i.p. (4 × 106 cells/200 µL), or 
(C, F) i.t. (1 × 106 cells/50 µL). Images were recorded (A–C) in live animals at different time points, and (D–F) 
in main organs, liver (1), spleen (2), kidney (3), lungs (4), and brain (5), collected at the endpoint (72 h). Prone 
representative images show DIR signal accumulation in the brain for all administration routes examined, 
especially at 24–72 h. Accumulation of labeled macrophages was also observed in the main peripheral organs.
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mass compared to other organs. In fact, when fluorescent accumulation levels were normalized to the mass of the 
excited organ (RFU/g), the highest BMM uptake was observed in the spleen and lungs (Supplementary Table S3).
Biodistribution of 64Cu‑labeled macrophages in Parkin Q311(X)A mice by PET. Next, biodistri-
bution of adoptively transferred cell-carriers in PD and WT mice was studied by PET imaging, a highly sensi-
tive technique that detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide. For this 
purpose, autologous BMM were labeled with 64Cu, and PD or WT littermates received a single injection of 64Cu-
BMM (48.0 ± 2.8 µCi/1 × 106 cells/50 µL/mouse, N = 4) through i.v., i.p., or i.t. routes. Unlike the IVIS experi-
ments described above, the comparable dose of 64Cu-labeled macrophages was used for all three administration 
routes in this experimental setup. The representative images of PD mice injected with 64Cu-BMM through i.v., 
i.p., and i.t. routes at various time points (up to 48 h) are shown on Fig. 4A. 64Cu-BMM brain levels for each 
administration route are shown in Supplementary Table S4. To quantify 64Cu-BMM levels, PD and WT mice 
with a single injection of radioactively-labeled macrophages were sacrificed at the endpoint (48 h), perfused, 
main organs and blood were harvested, and radioactivity levels were assessed using gamma counter (Fig. 4B). 
Individual values of the injected dose (%ID/g) for each animal are presented in Supplementary Tables S5–S7. 
Consistent with the results of IVIS experiments, the levels of 64Cu-BMM in the brain of PD mice with i.t. injec-
tions were significantly greater than those in i.v. and i.p. injected mice (Fig. 4A, B). Furthermore, the amount of 
BMM accumulated in PD mouse brain increased in a row: i.v. < i.p. < i.t. and for all injection routes was signifi-
cantly greater than in WT littermates (Fig. 4B). The superior brain bioavailability for adoptively transferred mac-
rophages, up to 8.1% of injected dose/g, was confirmed for PD mice at 48 h after a single i.t. injection. Of note, 
the brain/blood ratio in mice with i.t. injected macrophages also was significantly greater than in those treated 
i.v. and i.p. (Fig. 4C). Moreover, for all three administration routes, the brain/blood ratios of 64Cu-BMM in PD 
mice were significantly greater than those in WT mice (Fig. 4C), suggesting preferential transport and accumu-
Figure 2.  Biodistribution of DIR-labeled BMM in healthy mice by IVIS. DIR-labeled BMM were administered 
in healthy mice (12 mo. of age) (A, D) i.v. (4 × 106 cells/200 µL), (B, E) i.p. (4 × 106 cells/200 µL), or (C, F) 
i.t. (1 × 106 cells/50 µL). Images were recorded (A–C) in live animals at different time points, and (D–F) in 
main organs, liver (1), spleen (2), kidney (3), lungs (4), and brain (5), collected at the endpoint (72 h). Prone 
representative images of animals i.v., and i.p. suggest that DIR-BMM accumulate in the brain, although to 
a much lesser extent than same treatments in Parkin Q311(X)A mice (Fig. 1). Little if any DIR signal was 
observed in live animals after i.t. administration in healthy animals. Accumulation of labeled macrophages was 
also observed in the main peripheral organs.
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Figure 3.  Quantification of BMM accumulation in the main organs of PD and WT mice. Parkin Q311(X)
A mice (12 mo. of age) were injected with DIR-BMM using different routes of administration and imaged by 
IVIS. Wild type mice were used as healthy controls. (A) Quantification of fluorescence levels in the brain area 
of PD mice (filled symbols) or WT animals (empty symbols) injected with DIR-BMM through i.v. (circles), 
i.p. (squares), or i.t. (triangles). The highest levels were detected in PD mice with i.p. and i.t. administrations at 
24–72 h time frame. Accumulation levels of BMM in PD mouse brain were significantly greater than those in 
WT littermates. (B) At the endpoint (72 h), mice were sacrificed, perfused, and fluorescent levels of main organs 
(i.e. liver, spleen, kidney, lungs, and brain) were assessed by IVIS Aura software. The highest BMM accumulation 
was recorded in liver, spleen, and lungs. The amount of cell-carriers was significantly greater in the brain area 
of PD mice compared with WT littermates (insert). Values are the means ± SEM (N = 4), *p < 0.05; **p < 0.005 
compared with WT healthy mice; #p < 0.05 compared to PD mice injected through i.v. route. Individual data 
points shown in Supplementary Tables S1 and S2.
Figure 4.  Biodistribution kinetics of 64Cu-labeled macrophages in Parkin Q311(X)A and WT mice by PET. 
Radioactively-labeled BMM were injected into PD or WT mice (12 mo. of age) though i.v., i.p., or i.t. routes 
(2.5 × 106 cells/50 µL). The animals were imaged by PET over 48 h-time period after the injection (A). At 
the endpoint (48 h), mice were sacrificed, perfused, and the radioactivity in the blood and main organs was 
measured. Panels present (A) representative PET images, (B) percentage of the injected dose (%ID/g), (C) brain/
blood ratio, and (D) brain/muscle ratio. The greatest brain accumulation of 64Cu-BMM was detected in PD mice 
with i.t. injections. The amount of 64Cu-BMM accumulated in the PD mouse brain was significantly greater than 
those in WT animals. Values are the means ± SEM (N = 4), *p < 0.05; **p < 0.005 compared with WT healthy mice 
(B, C), or i.v. injections (D). Individual data points shown in Supplementary Tables S4–S6.
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lation of BMM in the inflamed brain in PD animals. The same pattern was observed for the brain/muscle ratio 
at 48 h time point (Fig. 4D). Finally, as expected, considerable amounts of macrophages deposited in the main 
peripheral organs; although, i.t. route resulted in decreased levels in peripheral organs and increased amount of 
BMM in the brain compared to i.v. and i.p. routes (Fig. 4B).
Biodistribution of 19F‑labeled BMM in Parkin Q311(X)A mice by MRI. Fluorine 19 (19F) imaging is 
a technique utilizing non-radioactive version of fluorine in MRI scanners. This technique takes advantage of the 
minimal background signal in the body; there is very little endogenous fluorine. Furthermore, the perfluorocar-
bon agents are relatively inert and nontoxic, and have been proposed for applications such as blood substitutes, 
treatment of retinal detachment, ultrasound contrast agents, etc. Thus, the lack of ionizing radiation and no 
reduction in signal due to radioactive decay confers advantages to perfluorocarbon MR techniques as a method 
to perform cell tracking for clinical purposes. Therein, we validated the 19F tracking of BMM into the brain in 
Parkin Q311(X)A mice, and laid the foundation for translating this drug treatment technique in humans. For 
this purpose, BMM were labeled with 19F (CS-ATM DM Red, Celsense, Inc., Pittsburgh, PA), and the accumula-
tion of 19F-BMM in PD mouse brain after i.t. injection was studied by MRI (Fig. 5). Dual mode optical and 19F 
MRI images confirmed that significant amount of i.t. administered BMM can reach the brain, especially at 48 h 
time point.
Delivery of reporter and therapeutic genes via pre‑transfected macrophages to the brain in 
Parkin Q311(X)A mice. Based on the results of IVIS, PET and MRI experiments, we selected the i.t. injec-
tion as the preferred route of administration of pre-transfected BMM for the delivery of reporter and therapeutic 
genes to the brain in Parkin Q311(X)A mice. For the reporter gene delivery study, the BMM cells transfected by 
electroporation with plasmid encoding a reporter gene, luciferase (Luc), Luc-pDNA were injected into PD mice, 
or their WT littermates through i.t. route. The luciferase expression levels in the brain regions (frontal cortex, 
midbrain, cerebellum, and pons) were examined 48 h after the single injection. To account for auto-lumines-
cence, the relative luminescence values obtained for control animals injected with saline were subtracted from 
those injected with Luc-BMM for each brain region. Significant luminescence in Luc-pDNA/BBM treated ani-
mals was recorded in all brain sub-regions of both PD and WT mice (Fig. 6A). Individual values of the luciferase 
expression levels for each animal are presented in Supplementary Tables S8 and S9. Consistent with BMM brain 
biodistribution results obtained by IVIS (Figs. 1, 2, 3) and PET (Fig. 4) studies, the Luc expression in the brain of 
PD mice was significantly greater than those in WT littermates (Fig. 6A). Specifically, luminescence levels in the 
midbrain, cerebellum and pons of PD mice were up to 40 times higher than those in WT animals. No differences 
in Luc levels were found in the blood of PD and WT animals. We suggest that Luc-BMM targeted inflamed brain 
tissues in PD animals, resulting in overexpression of the encoded gene (Luc). Thus, pre-transfected adoptively 
transferred macrophages provided a sustained expression of the encoded protein in the inflamed brain. Luc 
brain/blood ratio in PD mice was also significantly (p < 0.005) greater than those in WT healthy mice (Fig. 6B).
For the therapeutic gene delivery studies, Parkin Q311(X)A mice were injected i.t. with GDNF-transfected 
BMM, and GDNF-expression levels were examined in different brain regions 48 h after the administration 
(Fig. 6C). Individual values of the GDNF levels for each animal are presented in Supplementary Tables S10. 
The obtained data clearly demonstrate that a single injection of GDNF-BMM resulted in significant increases of 
GDNF expression in all brain regions examined. Similar to Luc expression, the highest levels of the GDNF was 
detected in pons. Consistently to the Luc-BMM studies, no significant increases in the blood GDNF levels were 
detected in the GDNF-BMM treated animals compared to saline-injected control group (Fig. 6C). Together, the 
studies demonstrated that cell-carriers efficiently target affected brain sub-regions in PD mice and deliver their 
therapeutic cargo.
Absence of cytotoxic effects in the mouse brain upon treatment with GDNF‑transfected 
macrophages. To evaluate possible offsite toxicity of the transfected macrophages, healthy WT mice were 
injected i.t. with GDNF-BMM, or the same amount of sham BMM. Control group of mice was injected with 
saline. The animals were sacrificed 48 h after the injection, and the levels of pro-inflammatory cytokines and 
chemokines, including RANTES, MCP-1, TNF-a, and IL-6 were assessed in the brain, as well as in main organs; 
brain, kidney, spleen and liver by membrane-based antibody arrays and confirmed by colorimetric sandwich 
Figure 5.  Biodistribution of 19F-labeled macrophages in Parkin Q311(X)A mice over time by MRI. 19F- labeled 
BMM were injected i.t. into PD mice (12 mo. of age, 1 × 106 cells/50 µL) and 1H/19F fusion image was obtained. 
Anatomic image is represented in gray scale with cell loading represented by the color. A phantom standard 
is external to the animal. Representative dual mode brain MR images show significant accumulation of i.t. 
administered BMM in the brain, especially at 48 h time point.
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ELISA (Fig. 7). Individual values of the inflammatory signals levels for each animal are presented in Supplemen-
tary Tables S11–S14.
No signs of increased inflammation in the brain were detected. Moreover, administration of GDNF-trans-
fected macrophages slightly reduced expression of all pro-inflammatory signals in the brain, compared to con-
trol saline-injected animals (Fig. 7A–D). Of note, this phenomenon may be due to a particular subset of M2 
cell-carriers differentiated with MCSF that show mild neuroprotective effects themselves as reported  earlier47. 
Next, the effect of GDNF-BMM and sham BMM administration on the expression of inflammatory molecules, 
3-nitrotyrosine (3-NT), NF-kb, and P62, were evaluated in healthy mice, and expressed as a ratio of expression 
of these molecules and that of housekeeping protein, β-actin (Supplementary Figure S3). In consistence with 
the expression levels of chemokines and cytokines, adoptive transfer of cell-based formulations did not signifi-
cantly affect the levels of 3-NT, NF-kb, and P62 in the brain. The administration of sham BMM increased NF-kb 
and p62 levels in kidney, and spleen, however, injection of GDNF-BMM eliminated this effect (Supplementary 
Figure S3). Finally, no differences in post-synaptic density (PSD-95) were detected in the brain of GDNF-BMM 
or sham BMM injected mice (Supplementary Figure S4A, B), indicating absence of toxic effects of macrophage-
based drug delivery system on the synaptic transmission. Of note, some increases of glutamate receptor levels, 
NMDR2A and NMDR2B, were recorded upon administration of sham BMM and GDNF-BMM, respectively 
(Supplementary Figure S4B, C). Overall, no significant offsite toxicity was found in the brain upon GDNF-BMM, 
or sham BMM injections. The slight cytotoxic effects in peripheral organs, kidney, and spleen, observed in ani-
mals injected with sham BMM were eliminated, when the GDNF-transfected macrophages were administered.
Discussion
Cell-based drug delivery systems have a potential as a treatment modality for CNS disorders. However, this field 
is not well developed, and relatively little research has been done to advance these novel cell-based therapeutic 
agents. It was long time demonstrated that macrophages have extraordinary ability to cross body barriers, includ-
ing the BBB, and reach the CNS, especially during a neurodegenerative  process51. Therefore, we posit that the 
chronic inflammation in the brain at pathological conditions provides an opportunity for site-specific delivery 
using inflammatory response cells as vehicles for different potent therapeutics, including genes, proteins and low 
molecular compounds. In particular, we have developed cell-based drug delivery systems, in which immune cells 
are non-virally transfected, ex vivo, with pDNA encoding therapeutic proteins, and then systemically adminis-
tered into mice with induced brain neurodegeneration, where they migrate to the sites of inflammation resulting 
in sustained expression of these therapeutics and prolonged neuroprotective  effects44,47.
The critical information about biodistribution of cell-carriers upon different routes of administration would 
allow to optimize decisions on dosing, treatment frequency, and other clinical and regulatory parameters. Herein, 
we report that i.t. administration is the most efficient way to deliver macrophage-based drug formulations to the 
inflamed brain in the transgenic mouse model of PD, Parkin Q311(X)A mice. First, IVIS studies demonstrated 
that all examined routes of administration, namely i.v., i.p., or i.t. injections, provided considerable amount of 
fluorescently labeled macrophages in the PD mouse brain. A prolonged sustained accumulation of cell-carriers 
Figure 6.  Reporter and therapeutic gene expression in brain of Parkin Q311(X)A mice after single i.t. injection 
of pre-transfected BMM. (A) Luc-transfected BMM (A, B) were injected through i.t. route (2.5 × 106 cells/50 µL) 
to PD mice (black bars) or WT mice (striped bars). Mice were sacrifices 48 h after injection, perfused, brains 
were harvested and luciferase activity was measured in different brain regions [i.e. frontal cortex (1), midbrain 
(2), cerebellum (3), and pons (4)), and blood (5)]. Luciferase activity in each brain region was significantly 
greater in PD mouse brain regions than those in WT counterparts (A). Total brain/blood ratio of luciferase 
activity in PD mice was 25 times greater than in WT mice (B), indicating that BMM target inflamed brain 
tissues. (C) PD mice were injected with the same amount of GDNF-transfected BMM through i.t. route (black 
bars), or saline (white bars). Mice were sacrifices 48 h after injection, perfused, brains were harvested and GDNF 
expression was measured in different brain regions by ELISA. GDNF levels in each brain region were greater in 
PD mouse brain regions injected with GDNF-BMM than controls injected with saline. Negligible differences in 
GDNF levels in the blood were observed. Values are means ± SEM (N = 6). *p < 0.05 compared to WT healthy 
mice (A, B), or saline injected control mice (C). Individual data points shown in Supplementary Tables S8–S10.
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in the mouse brain with maximal amount at 48–72 h after single injection was recorded. In addition to the brain 
accumulation, a substantial amount of adoptively transferred macrophages was detected in the spinal column 
in PD mice, especially after i.t. administration. This may have additional therapeutic benefits, as a widespread 
alpha-synucleinopathy was shown not only in the brain, but also in the spinal cord of PD  patients52. Thus, the 
delivery of therapeutics to the spinal cord may improve some nonmotor symptoms including urinary, sexual, and 
gastrointestinal, as well as of some motor symptoms. Next, we confirmed BMM accumulation in the brain in PD 
mice by PET with 64Cu-labeled macrophages. To have quantitative comparison for each administration route, the 
same dose of radioactively labeled macrophages was utilized in these settings. The results of PET experiments 
clearly demonstrated that i.t. administration lead to the highest accumulation of macrophages in the brain of 
Parkin Q311(X)A mice, with up to 8.1% of the injected dose was detected. The MRI studies with 19F-labeled 
BMM confirmed significant amount of i.t. administered BMM can reach the brain, especially at 48 h time point. 
We hypothesized that i.t. route allows to avoid entrapment of significant portion of BMM in peripheral organs, 
specifically, liver, lungs, and spleen, which was observed in case of i.v. and i.p. injections.
Surprisingly, i.p. administration resulted in significantly greater BMM levels in the brain compared to i.v. 
injection. We speculated that in addition to BMM penetration across the BBB brain from the bloodstream 
(Fig. 8A), a portion of i.p. injected macrophages may also reach the brain through lymphatic system (Fig. 8B). In 
fact, the meningeal  lymphatics50 have been recently recognized as an important player in the complex circulation 
and exchange of molecular and cellular contents between the cerebrospinal fluid (CSF) and the interstitial fluid 
(ISF)53. Indeed, the perfusion procedure, which was carried out at the endpoint of IVIS and PET experiments, 
allowed to clear out the luminal space from circulating in the blood stream cell-carriers provided more accurate 
information about the amount of macrophages entered the brain tissues. However, it does not distinguish between 
the cells associated with the luminal wall and the brain parenchyma. The more comprehensive understanding of 
how adoptively transferred macrophages reach the inflamed brain upon different administration routes warrant 
further investigations.
Equally important, in consistence with our previous  reports44–46,54,55, we demonstrated here the superior 
accumulation levels of autologous macrophages in the PD mouse brain compared to their WT littermates. This 
effect was obtained for all routs of administration. We suggest that brain inflammation developed during the 
disease progression, and release of various cytokines and reactive oxygen species (ROS) by activated microglia 
attracted macrophages providing targeted transport of cell-carriers to the brain.
Figure 7.  Effect of BMM administration on the levels of inflammatory signals in mice. Healthy WT mice were 
injected with saline (white bars), sham BMM (stripped bars), or GDNF-transfected BMM (black bars), and the 
inflammation signals in the main organs was assessed by the levels of RANTES (A), TNF-a (B), MCP-1 (C), IL-6 
(D). No significant increases of inflammatory signals were found in the brain. Some slight increases in RANTES, 
and MCP-1 were registered in spleen and liver (A, C). TNF-a levels were significantly decreased in spleen upon 
sham BMM injection. Values are means ± SEM (N = 10). *p < 0.05 compared to saline-injected control mice. 
Individual data points shown in Supplementary Tables S11–S14.
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The most significant observation was made for PD mice that were i.t. injected with autologous macrophages 
pre-transfected ex vivo with reporter Luc and therapeutic GDNF genes. Genetically modified cell-carriers accom-
plished a site-specific delivery of the encoded gene to local areas of the disease, where the inflammatory processes 
are active. Indeed, Luc activity in the PD mouse brain was considerably greater (up to 40 times) than in those 
in healthy WT littermates. Moreover, a single i.t. injection of GDNF-BMM resulted in significant increases of 
GDNF levels in all examined brain regions, including pons, midbrain, frontal cortex, and cerebellum. Essential, 
no increases in GDNF blood levels were recorded. We hypothesized that transfected ex vivo and adoptively 
transferred macrophages can accomplish horizontal gene transfer to the neighboring brain cells resulting in 
transfection of brain tissues. Thus, pre-transfected macrophages serve as “donors” that pass or “horizontally 
transfer” the gene to acceptor cells. In this respect, we demonstrated recently that transfected macrophages 
can pass pDNA to muscle  cells55, and siRNA to cancer  cells56, causing significant antitumor effects. In addition, 
GDNF-BMM can also deliver the overexpressed neurotrophic factor. Our earlier in vitro experiments indicate 
that genetically modified macrophages express GDNF up to a week after transfection (~ 1.8 ng/mg protein on day 
one) and release it to the conditioned media (~ 16.1 ng/mL) over 7 days after transfection. Finally, absence offsite 
effects in the brain upon adoptive transfer GDNF-transfected macrophages or sham BMM that manifested in the 
lack of increases of pro-inflammatory cytokines and chemokines levels, as well as unchanged synaptic activity 
in the brain was demonstrated. Noteworthy, some signs of increased inflammation were recorded in peripheral 
organs, kidney, and spleen, in case of sham BMM injection that were alleviated when GDNF-macrophages were 
administered. In this respect, using human umbilical cord blood monocytes (HUCBM) in future clinical trials 
may be more beneficial, as it was reported that these cells have protective activities by releasing neurotrophic and 
anti-inflammatory factors, and even can rescue brain cells from hypoxic-ischemic  injury57. Using these cells for 
gene delivery could have supplementary therapeutic benefits. Altogether, macrophages may pose an advanta-
geous and efficient delivery carrier for a spectrum of various degenerative, cancerous, and infectious disorders.
Methods
Plasmids and reagents. The plasmid encoding the reporter gene luciferase (Luc) (gWILuc) and Human 
GDNF cDNA (NM_199234) were purchased from Gene Therapy Systems, (San Diego, CA), and OriGene 
(Rockville, MD), respectively. The sequence and condition for plasmids expansion can be found in our ear-
lier  publication49. A lipophilic fluorescent dye, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindo-carbocyanine iodide 
(DIR), was purchased from Thermo Fisher Scientific (Waltham, MA). Murine macrophage colony-stimulating 
factor (MCSF) was purchased from Peprotech Inc (Rocky Hill, NJ).
Cells and animals. Primary bone marrow-derived cells extracted from murine femurs (wild type litter-
mates of Parkin Q311X(A) female mice, 2 months old) as described  in20.
Two breeding pairs of Parkin Q311X(A) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) 
12 weeks of age, and were treated in accordance to the Principles of Animal Care outlined by National Institutes 
of Health and approved by the Institutional Animal Care and Use Committee of the University of North Carolina 
at Chapel Hill. Several cohorts of transgenic mice as well as their wild type controls were bred in house. The 
genotyping of pups was carried by PCR analysis of Parkin Q311X(A) gene was performed for parents, a nega-
tive control wild mouse, and several mice generations according to manufacturers protocol. Mice were housed 
in a temperature and humidity-controlled facility on a 12 h light/dark cycle and food and water were provided 
ad libitum. According to NIH policy on Sex as a Biological Variable, both male and female mice were used in 
each group in 1:1 proportion. Significant sex differences were not detected in the analyses.
Figure 8.  Schematic representation of different pathways for adoptively transferred macrophages to the brain. 
Autologous macrophages transfected with reporter or therapeutic—encoding pDNA were injected via i.v., i.p., or 
i.t. routes. Different ways of brain entrance across (A) the BBB, or (B): CSF barrier are shown. (A) Macrophages 
injected through i.v. or i.p. routes cross the BBB and deliver the encoded proteins to the parenchyma. (B) In 
addition, macrophages injected i.p. may enter the brain through lymphatic system. Macrophages administered 
through i.t. route mainly enter through the CSF barrier.
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11818  | https://doi.org/10.1038/s41598-020-68874-7
www.nature.com/scientificreports/
Transfection of macrophages. BMM were transfected by electroporation according to manufacturer’s 
protocol with some modifications. Briefly, BMM (50 × 106 cells) were spanned down at 1,000 RPM for 5 min, 
re-suspended in 700 µL electroporation buffer (Neon Transfection system, Thermo Fisher Scientific) and sup-
plemented with 30 µg Luc-pDNA (300 µL), or GDNF-pDNA (300 µL) . The aliquots of cell suspension with 
Luc-pDNA (100 µL) were placed into electroporation cell, and electroporated at following setup: voltage 1,400; 
width 20; Pulses 2. Then, the cells were supplemented with 1 mL PBS, and centrifuged at 125G for 5 min. The 
supernatant was removed, and pellet was re-suspended in saline buffer and injected in PD or WT mice. To 
account for the expression levels of luciferase, a portion of the cells was cultured in CCM media for 24 h, then 
washed 3X with PBS, and lysed with luciferase lysis buffer (Promega, Madison, WI). The luciferase activity levels 
in BMM were assessed by luminescence (N = 4) and expressed in relative fluorescent units (RFU). Total lucif-
erase activity in Luc-BMM was 693.560 × 106 RFU/106 cells. The GDNF levels in the cells were assessed by ELISA 
(Human GDNF ELISA kit, #EHGDNF, ThermoFisher Scientific, Waltham, MA). In addition, GDNF-BMM can 
also deliver the overexpressed neurotrophic factor. GDNF-transfected macrophages showed about 1.8 ng/mg 
protein on day one after transfection”.
Administration of cell‑based formulations via different routes. Three different routes of adminis-
tration were utilized: i.v., i.p., and i.t. injections. For i.v. administration route, PD or WT mice were injected with 
a BMM-based formulation (50–200 µL) intra-tail vein with the use of a restraining devise. For i.p. administration 
route, mice were injected into the left lower quadrant of the abdomen (50–200 µL) without restraining devise. 
For i.t. administration route, mice were anesthetized with 3% isoflurane, and the fur at the posterior end was 
shaved. The BMM-based formulation (50 µL) was slowly injected between the groove of L5 and L6 vertebrate.
Kinetics of biodistribution of autologous macrophages in Parkin Q311(X)A mice and WT 
healthy littermates by IVIS. To track systemically injected cell-carriers in PD and WT mice, BMM were 
labeled with DIR lipophilic dye (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s protocol. Briefly, 
BMM (1 × 106  cell/mL) were incubated with 7 µM DIR in PBS for 20 min at 37C. Followed incubation, the 
cells were spin down and washed 3 × with ice-cold PBS and re-suspended in saline. To establish background 
fluorescence levels, animals were imaged before the BMM administration. Then, Parkin Q311X(A) mice (12 
mo. of age) and their WT littermates were injected with DIR-labeled BMM, via i.v., or i.p., or i.t. routes. In this 
experiment we used maximal dose and volume of cell suspension for each route of administration (specifically, 
4 × 106 cells/200 µL/mouse for i.v. and i.p. injections, and 1 × 106 cells/50 µL/mouse for i.t. injections), and the 
animals were imaged by Xenogen IVIS Optical Imaging System. The conditions of this experiment were set up 
for a maximal volume of the cell suspension injected that is allowed for each route of administration. At the 
endpoint (72 h), animals were sacrificed and perfused as described  earlier48, main organs were removed, washed, 
post-fixed in 10% phosphate-buffered paraformaldehyde, and evaluated by IVIS Aura software (Spectral Instru-
ment Imaging, Tucson, AZ, USA). The background fluorescent level (approximately 0.2–0.3 × 105 RFU) were 
subtracted from the levels at each time point for each mouse and plotted versus time.
Labeling BMM with celsense for MRI studies. BMM were labeled with 19F (CS-ATM DM Red, 
Celsense Inc., Pittsburg, PA). CS-ATM is an aqueous colloidal nanoemulsion of a perfluorocarbon polymer 
with a red fluorescent label. This compound enables dual mode optical and 19F MRI imaging in small animals. 
For this purpose, BMM (4 × 106 cell/T25 flask) were supplemented with 0.32 mL Celsense solution (3 mg/mL) 
and incubated at 37 °C for 4 h. Then, labeled 19F-BMM were collected, washed 3X with ice-cold PBS, and re-
suspended in saline. The labeling efficiency was evaluated by NMR with a fluorine probe with serial dilutions. A 
global calibration curve was determined based on BMM concentration versus NMR 19F signal. Serial dilutions of 
19F-BMM were imaged utilizing the 9.4 T small animal MRI and 400 Hz NMR to calibrate concentration curves 
between the modalities. Next, ParkinQ311(X)A mice were i.t. injected with 19F-BMM (2 × 106 cell/50 µL/mouse) 
and brain images were obtained over 120 h after the injection on the 9.4 T small animal scanner with a custom 
dual mode 1H/19F volume coil using conventional sequences for anatomic (1H T2 RARE,1H T1 FLASH) and 
functional localization (19F T1 RARE). Animals with a sham injection served as a control.
Labeling BMM with 64Cu for PET imaging and biodistribution studies. To track the brain targeting 
efficiency of BMM cells administered via different routes, BMM were labeled with 64Cu as described  earlier58. 
Briefly, BMM were incubated with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (64Cu-PTSM) in 
1 mL serum free medium at 37 °C for 1.5 h, and then washed with ice-cold PBS (pH 7.4). Parkin Q311X (A) 
mice (12 mo. of age) and their WT littermates were injected with 64Cu-BMM (48.0 ± 2.8 µCi/1 × 106 cells/50 µL/
mouse) via i.v., i.p., or i.t. administrations, and imaged using SuperArgus PET/CT system at 1 h, 24 h and 48 h 
post-injection. After 48 h post-injection PET scan, the animals were euthanized. The brain and blood were col-
lected and the accumulation of 64Cu-BMM was measured using gamma counter (2,470 Wizard, Perkin Elmer). 
The results were presented at percentage of injected dose per g of tissue (%ID/g).
Luciferase activity and GDNF levels in the brain and main peripheral organs. Parkin Q311(X)
A mice (12 mo. old, N = 6) and their healthy WT littermates were injected with Luc-BMM (2.5 × 106 cells/50 µL) 
through i.t. route of administration. Followed 48 h mice were anesthetized with ketamine/xylazine cocktail and 
subjected to transcardial perfusion with ice-cold PBS for 5 min following 5 min of perfusion with 4% ice-cold 
paraformaldehyde (PFA) in PBS. Blood samples (100 μL) at the endpoint were taken into heparin-coated micro-
hematocrit tubes (Braintree ScientificBraintee, MA), centrifuged for 5 min at 400×g, and luminescence levels 
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were recorded in plasma. Brain was removed, washed in ice-cold saline, different brain regions (frontal cortex, 
midbrain, cerebellum, and pons) were dissected, blotted and weighed. The brain samples were supplemented 
with 0.5 mL of tissue solubilizer and then homogenized in a glass tissue homogenizer (Tissue-Tearor, BioSpec 
Products, Inc., Bartlesville, OK). The luciferase activity in 10  μL tissue homogenates was quantified using a 
TD20/20 or Glomax 20/20 luminometer (Promega, Fitchburg, WI) for an integration period of 20 s and 10 s 
respectively and normalized per mg of tissue as described  before55.
To examine GDNF levels in the brain tissues in PD mice by ELISA, Parkin Q311(X)A mice (12 mo. old, N = 6) 
were injected with GDNF-BMM (2.5 × 106 cells/50 µL) through i.t. route. PD mice injected with saline were used 
as a control group. Followed 48 h, mice were sacrifices, perfused with PFA, brain was removed, dissected to dif-
ferent regions (frontal cortex, midbrain, cerebellum, and pons), and homogenized as described above. Blood 
samples were also collected. The lysates were spun 13,000 G for 10 min, supernatant was collected and added 
to the 96-well plate (100 µL/well) pre-coated with anti-human GDNF (Human GDNF ELISA kit, #EHGDNF, 
ThermoFisher Scientific, Waltham, MA). The plate was covered and incubated at RT for 2.5 h, then washed 4X 
with PBS, biotinylated antibody was added (100 µL/well) and incubated at RT for 1 h. Then, the plate was washed 
4X, the streptavidin-HRP reagent (100 µL/well) was added, and incubated at RT for another 45 min. The plate was 
washed 4 × with PBS and TMB substrate (100 µL/well) was added. The color was developed at RT in the dark for 
30 min and Stop solution (50 µL/well) was added. Absorbance was measured at 450 nm. The amount of GDNF 
was assessed based on the provided by manufacturer calibration curve and expressed in pg GDNF/mg protein.
Expression of cytokines and chemokines in the brain and main peripheral organs by ELISA and 
Western blotting. Organs were homogenized in cell lysis buffer (Thermo Scientific, Waltham, MA, USA) 
and the levels of interleukin (IL)-6, monocyte chemotactic protein-1 (MCP-1), regulated on activation, normal T 
cell expressed and secreted (RANTES) and tumor necrosis factor alpha (TNF-α) were measured by ELISA (R&D 
Systems, Minneapolis, MN, USA) as described  in49.
Protein was extracted using RIPA buffer (Thermo Scientific) supplemented with a mixture of protease 
and phosphatase inhibitors followed by SDS-PAGE protein separation. Immunoblots were labeled with pri-
mary antibodies against 3-Nitrotyrosine (NT)—1:200 (Abcam, ab110282), PSD-95—1:200 (Abcam, ab76115), 
NMDAR2B—1:200 (Abcam, ab65783), NF-kB—1:200 (Santa Cruz Biotechnology, sc8008), P62/SQSTM1—1:500 
(Novus Biologicals, NBP1—48,320) and β actin—1:200 (Santa Cruz Biotechnology, sc-47778) was used as inter-
nal control. Immunoblots were subsequently incubated with secondary antibodies conjugated to horseradish 
peroxidase (Millipore, Billerica, MA, USA), exposed to SuperSignal West Femto Substrate (Thermo Scientific) 
and visualized using a ChemiDoc imaging system (Bio-Rad,). Densitometric analysis was quantitatively meas-
ured using image J (NIH.gov).
Statistical analysis strategy. Previous studies guided our decisions regarding distributional assump-
tions, transformations of scales, and choices of estimators (mean vs. median, etc.). For each outcome measure 
in each experiment involving groups of N = 4, 6 or 10 mice, sample means were tabulated along with their cor-
responding standard errors (SEM): the estimated mean ± one SEM is an approximate 66% confidence interval. 
Hypothesis tests regarding treatment effects and differences between types (PD vs. WT) were performed using 
sets of pairwise two-sided t tests. The reported p values have not been adjusted for multiple comparisons. In the 
main analyses, rarely occurring missing data values were assumed to be caused by ignorable mechanisms. After 
the main analyses were completed, sensitivity analyses were performed to guide our level of trust in the main 
results by examining the their robustness/fragility; examples of these auxiliary computations include analysis of 
residuals, and examination of the impacts of influential observations, questionable data values, and alternative 
transformations of measurement scales (e.g., log10). Data values for the individual mice were tabulated for pres-
entation in the Supporting Information section. All statistical computations were performed using GraphPad 
Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and Microsoft Excel (Microsoft Corp., 2016).
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